A drug that targets a common mutation in

Maintenance treatment with single-agent azacitidine at a dose of 32 mg/m2 daily for five days did not lead to improved survival in patients with high-risk

Targeted therapies are designed to work against specific vulnerabilities in a cancer cell.

The targeted therapy drug venetoclax is designed to block the function of the B-cell lymphoma-2 (Bcl-2) protein, which normally works to prevent cell death.

Key Points
Recipient telomere length is independently associated with overall survival and NRM after transplantation for MDS.

Stem cell transplantation (SCT) offers many people with blood and bone marrow cancers hope for a potential cure. More than 17,500 stem cell transplants are performed in the U.S. annually.

Amer Zeidan, MBBS, MHS, Yale University School of Medicine and Yale Cancer Center, New Haven, Connecticut, discusses updated results from an ongoing retrospective study examining FLT3 testing trends, treatment patterns, and overall survival in patients with relapsed/

Administering 2 additional courses of

PURPOSE

Background
Haematopoietic stem-cell transplantation (HSCT) recipients are considered at high risk of poor outcomes after COVID-19 on the basis of their immunosuppressed status, but data from large studies in HSCT recipients are lacking. This study describes the characteristics and outcomes of HSCT recipients after developing COVID-19.